“…Although paclitaxel plus bevacizumab (PB) therapy is an effective chemotherapeutic regimen for HER2-negative advanced breast cancer (ABC), predictive markers for its effectiveness remain undefined. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…In previous studies, the tumor-associated surface antigen ERBB2 (HER2/neu) was identified as targetable in high-risk RMS. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…In clinical decision‐making, to decide the indication for adjuvant chemotherapy for estrogen receptor‐positive (ER+), human epidermal growth factor receptor‐2‐negative (HER2−), and node‐negative (n0) breast cancer patients, the accurate estimation of recurrence risk is essential. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…A propensity score matching was performed separately in the HER2-negative and HER2-positive cohorts, respectively. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Primary breast cancer tissue surgically removed was classified as ER(−)/PR(−)/HER2(+), and the same phenotype was maintained by DHSF-BR16 cells. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…LESSONS LEARNED: This is the first trial to explore the neoadjuvant therapy of pyrotinib in HER2‐positive operable and locally advanced breast cancer, in combination with epirubicin plus cyclophosphamide followed by docetaxel plus trastuzumab. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

Enlace del recurso
Enlace del recurso
Enlace del recurso

“…However, the clinical utility of HER2 is frequently tempered by the uncertainty regarding the accuracy of the methods currently available to assess HER2. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…SIMPLE SUMMARY: Hyperactivation of the PI3K/AKT/mTOR cell signalling pathway is an important and well-described mechanism of trastuzumab resistance in HER2-positive breast cancer. In cell-line models of acquired trastuzumab resistance generated in our laboratory, we demonstrate this type of activation, which is independent of HER2-mediated regulation. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Synchronous occurrences of gastric cancer positive for human epidermal growth factor receptor 2 (HER2+) and bladder cancer are rarely encountered in clinical practice. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…CONCLUSIONS: Physicians prefer chemotherapy over endocrine therapy for the treatment of patients with HR+/HER2– MBC who develop progression on palbociclib. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Herein, we established a novel HER2-positive breast cancer cell line from the pleural effusion of a drug-resistant metastatic breast cancer patient. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…In this study, these mice were transplanted with PBMCs derived from breast cancer patients (BC) and immunized with a human epidermal growth factor receptor 2 (HER2) peptide, CH401MAP, to analyze humoral immunity of BCs. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…We were informed that for the past 6 months, the 78-year-old lady has been living with her unwell 24-year-old granddaughter who has been divorced. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Patients were grouped according to the biological subtype of the tumor [luminal A, 28; luminal B, 9; human epidermal growth factor receptor 2 (HER2) positive, 14; triple-negative breast cancer (TNBC), 16]. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…We leveraged data from the HER Salt Lake Contraceptive Initiative, a prospective cohort study with patient surveys at baseline, one month, and three months. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…METHODS: We evaluated the relations of the 21-gene recurrence risk score (RS) and the expression of cancer-related genes with metabolic factors and biomarkers of insulin and the insulin-like growth factor (IGF) axis, and examined the interactions between the 21-gene RS and these metabolic profiles on breast cancer recurrence in Chinese women with HR-positive, HER2-negative early-stage breast cancer. RESULTS: The 21-gene RS was inversely associated with body mass index ([BMI]β: −0.178 kg/m(2); P=0.040), the homeostasis model assessment of insulin resistance index ([HOMA-IR] β: −0.031; P=0.042), insulin (β: −0.036 uIU/ml; P=0.009), and C-peptide (β: −0.021 ug/L; P=0.014) and was positively associated with high-density lipoprotein cholesterol (β: 0.025 mmol/L; P=0.004), which were driven by the relation patterns between specific cancer-related genes and these metabolic profiles. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…The mainstay treatment for HER2-positive/HR-positive patients is anti-HER2 treatment combined with chemotherapy. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Existing HER2-targeting therapies significantly improved patient outcomes; still, designing these personalized treatments relies on accurate and comprehensive assessment of HER2 alterations. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso